Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients
Arthur E. Frankel, Jung Hee Woo, Chul Ahn, et al.
Blood (2014) Vol. 124, Iss. 3, pp. 385-392
Open Access | Times Cited: 215

Showing 1-25 of 215 citing articles:

Targeting cancer stem cell pathways for cancer therapy
Liqun Yang, Pengfei Shi, Gaichao Zhao, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 1541
Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm
Naveen Pemmaraju, Andrew A. Lane, Kendra Sweet, et al.
New England Journal of Medicine (2019) Vol. 380, Iss. 17, pp. 1628-1637
Open Access | Times Cited: 345
Going viral: chimeric antigen receptor T‐cell therapy for hematological malignancies
Saar Gill, Carl H. June
Immunological Reviews (2014) Vol. 263, Iss. 1, pp. 68-89
Closed Access | Times Cited: 309
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa, Elvira Pelosi, Arthur E. Frankel
Biomarker Research (2014) Vol. 2, Iss. 1
Open Access | Times Cited: 230
Chimeric antigen receptor T cell therapy: 25years in the making
Saar Gill, Marcela V. Maus, David L. Porter
Blood Reviews (2015) Vol. 30, Iss. 3, pp. 157-167
Closed Access | Times Cited: 212
Genetically engineered T cells for cancer immunotherapy
Dan Li, Xue Li, Weilin Zhou, et al.
Signal Transduction and Targeted Therapy (2019) Vol. 4, Iss. 1
Open Access | Times Cited: 207
Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches
Livio Pagano, Caterina Giovanna Valentini, Sara Grammatico, et al.
British Journal of Haematology (2016) Vol. 174, Iss. 2, pp. 188-202
Open Access | Times Cited: 179
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Marco Ruella, Michael Klichinsky, Saad S. Kenderian, et al.
Cancer Discovery (2017) Vol. 7, Iss. 10, pp. 1154-1167
Open Access | Times Cited: 175
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody–drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study
Naval Daver, Pau Montesinos, Daniel J. DeAngelo, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 3, pp. 388-399
Closed Access | Times Cited: 24
Concise Reviews: Cancer Stem Cell Targeted Therapies: Toward Clinical Success
Amar Desai, Yan Yan, Stanton L. Gerson
Stem Cells Translational Medicine (2018) Vol. 8, Iss. 1, pp. 75-81
Open Access | Times Cited: 159
Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases
John A. Hamilton, Andrew D. Cook, Paul P. Tak
Nature Reviews Drug Discovery (2016) Vol. 16, Iss. 1, pp. 53-70
Closed Access | Times Cited: 150
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa, Elvira Pelosi, Germana Castelli
Cancers (2019) Vol. 11, Iss. 9, pp. 1358-1358
Open Access | Times Cited: 130
Neoplasms derived from plasmacytoid dendritic cells
Fabio Facchetti, Marta Cigognetti, Simona Fisogni, et al.
Modern Pathology (2016) Vol. 29, Iss. 2, pp. 98-111
Open Access | Times Cited: 121
Blastic Plasmacytoid Dendritic Cell Neoplasm: State of the Art and Prospects
Maria Rosaria Sapienza, Alessandro Pileri, Enrico Derenzini, et al.
Cancers (2019) Vol. 11, Iss. 5, pp. 595-595
Open Access | Times Cited: 111
Classification and clinical behavior of blastic plasmacytoid dendritic cell neoplasms according to their maturation-associated immunophenotypic profile
Lourdes Martín‐Martín, Antonio López, María‐Belén Vidriales, et al.
Oncotarget (2015) Vol. 6, Iss. 22, pp. 19204-19216
Open Access | Times Cited: 107
Stem and progenitor cell alterations in myelodysplastic syndromes
Aditi Shastri, Britta Will, Ulrich Steidl, et al.
Blood (2017) Vol. 129, Iss. 12, pp. 1586-1594
Open Access | Times Cited: 107
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Francine Garnache‐Ottou, Chrystelle Vidal, Sabeha Biichlé, et al.
Blood Advances (2019) Vol. 3, Iss. 24, pp. 4238-4251
Open Access | Times Cited: 104
Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
Yuxin Liu, Jan Philipp Bewersdorf, Maximilian Stahl, et al.
Blood Reviews (2018) Vol. 34, pp. 67-83
Closed Access | Times Cited: 97
Treatment of blastic plasmacytoid dendritic cell neoplasm
Jill M. Sullivan, David A. Rizzieri
Hematology (2016) Vol. 2016, Iss. 1, pp. 16-23
Open Access | Times Cited: 92
Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
Fu Li, May Kung Sutherland, Changpu Yu, et al.
Molecular Cancer Therapeutics (2017) Vol. 17, Iss. 2, pp. 554-564
Open Access | Times Cited: 90
Targeted Diphtheria Toxin-Based Therapy: A Review Article
Fatemeh Shafiee, Marc G. Aucoin, Ali Jahanian‐Najafabadi
Frontiers in Microbiology (2019) Vol. 10
Open Access | Times Cited: 83
Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia
Wenbin Xiao, Alexander Chan, Michael R. Waarts, et al.
Blood (2020) Vol. 137, Iss. 10, pp. 1377-1391
Open Access | Times Cited: 83
CD123 a Therapeutic Target for Acute Myeloid Leukemia and Blastic Plasmocytoid Dendritic Neoplasm
Elvira Pelosi, Germana Castelli, Ugo Testa
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2718-2718
Open Access | Times Cited: 24
Blastic plasmacytoid dendritic cell neoplasm: a comprehensive review in pediatrics, adolescents, and young adults (AYA) and an update of novel therapies
Branko Cuglievan, Jeremy Connors, Jiasen He, et al.
Leukemia (2023) Vol. 37, Iss. 9, pp. 1767-1778
Open Access | Times Cited: 23
Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality
Ruyan Rahnama, Monika Kizerwetter, Yang Huilin, et al.
Journal for ImmunoTherapy of Cancer (2025) Vol. 13, Iss. 2, pp. e010763-e010763
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top